Head & Neck Cancers

Jameel Muzaffar, MD, discusses findings from the phase 2 portion of the FLX475-02 study examining tivumecirnon plus pembrolizumab in HNSCC.

The FDA has granted breakthrough therapy designation to petosemtamab in recurrent or metastatic head and neck squamous cell carcinoma.

Bernard A. Fox, PhD, discusses an off-the-shelf multivalent vaccine that contains cancer’s dark matter combined with anti–PD-1 and anti-GITR antibodies in head and neck cancer.

Jameel Muzaffar, MD, discusses a study of FLX475 plus pembrolizumab in patients with head and neck squamous cell carcinoma.

First-line treatment with the combination of Versamune HPV and pembrolizumab met a best overall response end point in recurrent/metastatic HNSCC.

Setanaxib plus pembrolizumab improved progression-free survival and overall survival in recurrent or metastatic head and neck squamous cell carcinoma.

A new drug application seeking the approval of toripalimab for the treatment of patients with nasopharyngeal carcinoma is under review in Hong Kong.

Frontline eftilagimod alpha plus pembrolizumab generated responses in patients with recurrent or metastatic HNSCC with negative PD-L1 expression.

Tivumecirnon plus pembrolizumab elicited responses in recurrent or metastatic head and neck squamous cell carcinoma after checkpoint inhibitor exposure.

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.

The galectin-9–targeted monoclonal antibody LYT-200 received FDA fast track designation for recurrent/metastatic head and neck squamous cell cancer.

Phase 1 data of TG4050 elicited tumor-specific immune responses that resulted in low relapse rates in patients with resected HPV–negative head and neck cancers.

Administration of atezolizumab after definitive local therapy did not improve EFS or OS in patients with head and neck squamous cell carcinoma.

Deborah J. Wong, MD, PhD, discusses the evaluation of atezolizumab vs placebo after definitive local therapy in high-risk, locally advanced HNSCC.

Alessandro Villa, DDS, PhD, MPH, discusses the incidence of oral toxicities in patients with head and neck cancer.

Anna Lee, MD, MPH, discusses key takeaways from a presentation on managing head and neck cancers that was given at the 2024 ACRO Summit.

NT219 in combination with cetuximab was safe and effective in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

The oncolytic virus product MVR-T3011 has received FDA fast track designation for recurrent or metastatic head and neck squamous cell cancer.

In case you missed it, read a recap of every episode of OncLive On Air recorded in February 2024.

Quad Shot radiation plus a checkpoint inhibitor significantly improved local control vs Quad Shot alone and was well tolerated as a palliative treatment for patients with advanced head and neck cancer.

TNO155 plus spartalizumab or ribociclib was well tolerated and demonstrated disease control in patients with advanced solid tumors.

A high rate of disease control was seen with the novel MDM2 inhibitor APG-115-alrizomadlin in patients with p53 wild-type salivary gland cancer.

Iopofosine plus EBRT elicited a 64% CR rate and was well tolerated in patients with locoregionally recurrent/metastatic head and neck cancer.

Adding lenvatinib to pembrolizumab improved ORR and PFS, but not OS, vs placebo for patients with head and neck squamous cell carcinoma.

The FDA has granted clearance for an investigational new drug application for a phase 1/2 safety lead-in trial investigating the engineered tumor-infiltrating lymphocyte KSQ-001EX in patients with melanoma, head and neck squamous cell carcinoma, and non–small cell lung cancer.